Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
NCT06946199

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-01-12

28

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.

CONDITIONS

Official Title

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years at time of informed consent
  • Diagnosis of adult-onset rheumatoid arthritis by 2010 ACR/EULAR criteria
  • Moderately to severely active rheumatoid arthritis
  • Positive rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) at screening
  • Inadequate treatment response or intolerance to tsDMARD and/or bDMARD therapies
Not Eligible

You will not qualify if you...

  • Abnormal clinical laboratory results at screening
  • Active infection
  • Received live vaccine within 4 weeks before screening
  • Presence of any other autoimmune disease
  • History of progressive multifocal leukoencephalopathy
  • History of primary immunodeficiency or hereditary complement deficiency
  • Central nervous system disease
  • Significant other medical conditions judged by investigator
  • Diagnosis or history of cancer within 5 years
  • Serious mental illness, alcohol or drug abuse, dementia, or conditions impairing ability to consent or follow treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Wuhan Union Hospital

Wuhan, Hubei, China, 430000

Actively Recruiting

Loading map...

Research Team

Q

Qiubai Li, Professor

CONTACT

D

Di Wu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here